Today, we’re entering an era in which data is now the next major competitive differentiator across every industry in the ...

Malicious JavaScript code delivered by the AppsFlyer Web SDK hijacked cryptocurrency, potentially in a supply-chain attack.

New attack waves from the 'PhantomRaven' supply-chain campaign are hitting the npm registry, with dozens of malicious packages that exfiltrate sensitive data from JavaScript developers.

Quadratic regression is a classical machine learning technique to predict a single numeric value. Quadratic regression is an extension of basic linear regression. Quadratic regression can deal with ...

President Donald Trump invited technology companies to the White House on Wednesday to commit to developing their own power generation as he tries to ease tensions over the cost of electricity used by ...

The momentum is already visible across the Phoenix metro area, where new chip fabrication plants and data center campuses are under construction. But success brings a critical challenge: how to ...

We introduce VeriStruct, a novel framework that extends AI-assisted automated verification from single functions to more complex data structure modules in Verus. VeriStruct employs a planner module to ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Shipping-container-based data centers have been introduced as building blocks for constructing mega-data centers. However, it is a challenge on how to interconnect those containers together with ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...